Leading the way in innovation for over 55 years, we build greater futures for businesses across multiple industries and 55 countries.
Our triple bottom line focuses on people, the planet, and purpose. Together we are ready to go the extra mile to empower communities while transforming countless lives and industries along the way.
We share news, insights, analysis and research – tailored to your unique interests – to help you deepen your knowledge and impact.
At TCS, we believe exceptional work begins with hiring, celebrating and nurturing the best people — from all walks of life.
Get access to a catalog of the latest news stories from across TCS. Discover our press releases, reports, and company announcements.
A hybrid approach to signal detection and management
Shubham Chaudhari
Domain Consultant, TCS ADD Platforms
Achyuth Tanay Kota
Domain Consultant, TCS ADD Platforms
Ashutosh Pachisia
Data Scientist, TCS ADD Platforms
You have these already downloaded
We have sent you a copy of the report to your email again.
All pharmaceutical products approved to be used in a marked setting have proven benefits but are also associated with adverse effects. The detection of such unknown risks is important to ensure the safety of patients. Signal detection and management in pharmacovigilance necessitates the ongoing monitoring of individual case safety reports (ICSR) to identify case reports of adverse events (AE) that are worthy for further exploration. Traditionally, signals are detected either qualitatively or quantitatively. Qualitative detection involves a deep analysis through manual assessment of the ICSR in an individual or cumulative manner, whereas the quantitative method involves statistical techniques such as disproportionality analysis.
In this white paper series, we propose a hybrid approach where the algorithm is fueled to assess a signal and manage it for effective grading based on a qualitative approach
Automating Third Party Data Transfer Through Digitized Electronic DTA
TCS ADD™ Risk-Based Quality Management Platform
Reimagining Reporting and Visualization During CDM
Advancing Regulatory Intelligence with Conversational, Generative AI
Learn how we can help you bring drugs to the market faster.
Talk to our experts